Another useful article: https://www.ncbi.nlm.nih.gov/pubmed/27723879

A similar estimate of chances of success.  Out of 640 products in late-stage, clinical trials about half failed due to inadequate efficacy (n = 195; 57%).

I would say that the odds of success are a bit higher since the trial has met recruitment targets and has survived a number of safety and futility analyses.

At this stage it is just a waiting game.  I like the odds but at the same time there is not much to do but accumulate a position and wait for the top line results.